Lapatinib, a reversible EGFR/HER1 and HER2 TKI, has shown modest activity in patients with HER2-positive metastatic BC (n = 104) who have received ≥3 lines of prior anticancer therapy and trastuzumab therapy [23]. Here, EGFR is linked to breast cancer.